



Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.



Available online at www.sciencedirect.com

ScienceDirect

journal homepage: www.e-jmii.com



Review Article

COVID-19 associated mucormycosis – An emerging threat

Chien-Ming Chao ^{a,b}, Chih-Cheng Lai ^c, Wen-Liang Yu ^{d,e,*}



^a Department of Intensive Care Medicine, Chi Mei Medical Center, Liouying, Tainan, 73657, Taiwan

^b Department of Dental Laboratory Technology, Min-Hwei College of Health Care Management, Tainan, 73657, Taiwan

^c Department of Internal Medicine, Kaohsiung Veterans General Hospital, Tainan Branch, Tainan, 71051, Taiwan

^d Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, 71004, Taiwan

^e Department of Medicine, School of Medicine, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan

Received 27 July 2021; received in revised form 22 November 2021; accepted 29 December 2021

Available online 13 January 2022

KEYWORDS

COVID-19;
Corticosteroid;
Diabetes mellitus;
Fungus;
Mucormycosis

Abstract Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly become a global threaten since its emergence in the end of 2019. Moreover, SARS-CoV-2 infection could also present with co-infection or secondary infection by other virus, bacteria, or fungi. Among them, mucormycosis is a rare but aggressive fungal disease and it mainly affects patients particularly with poorly controlled diabetes mellitus with diabetic ketoacidosis (DKA). We here did a comprehensive review of literature reporting COVID-19 associated with mucormycosis (CAM) cases, which have been reported worldwide. The prevalence is higher in India, Iran, and Egypt than other countries, particularly highest in the states of Gujarat and Maharashtra in India. Poor diabetic control and the administration of systemic corticosteroids are the common precipitating factors causing mucormycosis in the severe and critical COVID-19 patients. In addition, COVID-19 itself may affect the immune system resulting in vulnerability of the patients to mucormycosis. Appropriate treatments of CAM include strict glycemic control, extensive surgical debridement, and antifungal therapy with amphotericin B formulations.

Copyright © 2022, Taiwan Society of Microbiology. Published by Elsevier Taiwan LLC. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

* Corresponding author. Department of Intensive Care Medicine, Chi Mei Medical Center, Tainan, 71004, Taiwan. Fax: +886 6 2833351. E-mail addresses: ccm870958@yahoo.com.tw (C.-M. Chao), dtmed141@gmail.com (C.-C. Lai), Yuleon_md@yahoo.com.tw (W.-L. Yu).

Introduction

Coronavirus disease 2019 (COVID-19) caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) rapidly become a global threaten since its emergence in the end of 2019.¹ As of November 20, 2021, more than 255 million confirmed cases have been identified worldwide and more than 5 million deaths have been reported.¹ SARS-CoV-2 infection could present as asymptomatic, mild symptom, severe pneumonia, and acute respiratory distress syndrome (ARDS).^{1–3} Although respiratory tract symptoms and fever were the most common clinical presentations among symptomatic patients, extra-pulmonary involvements by COVID-19 include cardiac, gastrointestinal, hepatic, renal, neurological, olfactory, gustatory, ocular, cutaneous and hematological symptoms.⁴ Moreover, SARS-CoV-2 infections could also present with co-infections or secondary infections by bacteria, such as *Streptococcus pneumoniae*, *Staphylococcus aureus*, *Klebsiella pneumoniae*, and *Acinetobacter baumannii*; viruses such as influenza, coronavirus, rhinovirus/enterovirus, parainfluenza, metapneumovirus, and human immunodeficiency virus, and fungi, such as *Aspergillus* spp.^{5–10} In addition to these co-pathogens, many cases of mucormycosis among COVID-19 patients have been reported recently.^{11–18} Mucormycosis is a rare but aggressive fungal disease and it mainly affects patients with poorly controlled diabetes mellitus and severely immunocompromised patients.¹⁹ In contrast to aspergillosis, mucormycosis was rarely reported following viral infection.^{20–22} At present, the studies and knowledge about COVID-19 associated with mucormycosis (CAM) have been limited. Therefore, we did a comprehensive review of literature reporting mucormycosis in patients with COVID-19 to provide updated information.

Epidemiology

Since the outbreak of COVID-19, more and more cases of CAM have been reported.^{23–27} In UK, the post-mortem study of 10 several fatal COVID-19 cases in the early pandemic (between March 1 and April 30, 2020) showed one patient who had unexpected disseminated mucormycosis involving the lungs and brain.²³ In US, Placik et al. reported a fatal case of mucormycosis with necrotizing pulmonary infections and a bronchopleural fistula following COVID-19 in Arizona.²⁵ In India, Mehta et al. demonstrated a diabetic patient of rhino-orbital mucormycosis associated with COVID-19.²⁶ In Brazil, Monte Junio et al. showed an unusual case of gastric mucormycosis in an elderly patient with COVID-19.²⁴ In Italy, Paserol et al. reported one COVID-19 case who developed a pulmonary mucormycosis with extensive cavitory lesions.²⁷ Thereafter, more and more CAM cases have been reported in Egypt, the Netherlands, Iran, Japan, Spain, Mexico, and Austria.^{28–36} In contrast to other countries, India reported the most cases with a rapid increasing incidence.³⁷ As of May 28, 2021, at least 14, 872 cases of CAM have been found in India, in which the state of Gujarat had the highest incidence, with at least 3726 cases, followed by the state of Maharashtra.³⁷ The similar trend was reported in another large retrospective study of 2826 patients with COVID-19 associated rhino-orbital-cerebral

mucormycosis, in which the states of Gujarat (22%) and Maharashtra (21%) had the highest cases.³⁸ At the same time, the number of acute invasive fungal rhinosinusitis in a single center in Egypt was much higher in 2020 ($n = 29$) than 2017 ($n = 9$), 2018 ($n = 8$), and 2019 ($n = 10$).³⁹ A multicenter study in India showed that the prevalence of CAM was 0.27% among hospitalized COVID-19 patients, in which the prevalence was higher in COVID-19 managed in intensive care unit (ICU) than in general ward (25/1579 versus 28/10,517).¹³ Till now, almost 90% of the CAM cases were reported from India (Table 1),^{13,14,26,38,40–53} which may be attributed the following causes: (1) India has the second largest diabetic population and about 70% of them were not under control⁵⁴ and (2) the environmental factors in India - tropical and sub-tropical humid climate and high environmental temperature.⁵⁴

Pathogenetic roles of ketoacidosis and unbound iron

The patients developing diabetic ketoacidosis (DKA) are susceptible to mucormycosis. In a study testing the *in-vitro* growth of *Rhizopus oryzae*, a common etiologic agent of mucormycosis, in DKA serum, the acidotic conditions (pH 7.3–6.6) of serum would reduce the capacity of transferrin to bind iron, thus offering the unbound iron in the DKA serum to support the profuse growth of *R. oryzae*. DKA sera did not support fungal growth at two conditions of either iron-deficient status or at a serum pH greater than or equal to 7.4.⁵⁵ Clinical and animal model data have demonstrated that the presence of elevated available serum iron predisposes the host to mucormycosis due to the critical role of the ability of *Mucorales* to acquire host iron as a virulence factor.^{56,57} *Rhizopus* invades the epithelium via fungal spore coat proteins (CoH) binding to the host receptor of glucose-regulated protein 78 (GRP78) on the nasal and alveolar epithelial cells.^{58,59} The hallmark features of DKA including β -hydroxy butyrate (BHB), glucose, and iron components in DKA sera can increase surface expression of GRP78 in epithelial cells and fungal CoH expression. BHB also indirectly compromised the ability of transferrin to bind iron, thus increasing the available serum iron. Together with use of corticosteroid in a standard care of COVID-19 patients can further upregulate CoH3 and nasal GRP78,⁶⁰ thereby trapping the fungal cells within the rhino-orbital epithelium, leading to subsequent invasive diseases. These BHB-developed acidotic serum conditions extremely predispose to mucormycosis, but not to aspergillosis.^{60–62}

Interactions between COVID-19 and mucormycosis

Most cases of mucormycosis are temporally linked to COVID-19.⁶³ The surge in the number of cases of CAM is relevant to environmental characteristics and universal glucocorticoid use for severe COVID-19 cases, in addition to a previous well-known demographic factor of poor control for diabetes mellitus especially with DKA. The systemic use of corticosteroids is a double-edged sword in the therapy for cytokine storm and triggering for mucormycosis in the COVID-19

Table 1 Summary of reported COVID-19 associated mucormycosis from different geographic areas.

Geographic areas	Case no.	Age (yr)	Gender	Underlying condition	Lesion	Mortality	Author
United Kingdom	1					1 (100%)	
London	1	22	M	Obesity, hypothyroidism	Disseminated	Yes	Hanley et al. ²³
South America	2					2 (100%)	
São Paulo, Brazil	1	86	M	Corticosteroid use	Stomach	Yes	Monte Junior et al. ²⁴
Mexico City, Mexico	1	24	F	Obesity	Rhino-orbital	Yes	Waizel-Haiat et al. ³⁵
United States	9					7 (78%)	
New York	1	68	M	Heart transplant, DM	Cutaneous	Yes	Khatri et al. ¹⁶
New York	1	33	F	DM	Rhino-orbital-cerebral	Yes	Werthman-Ehrenreich et al. ³⁴
San Francisco, California	1	60	M	DM	Rhino-orbital	Yes	Mekonnen et al. ¹⁷
Riverside, California	1	79	M	Corticosteroid use	Pulmonary	no	Johnson et al. ⁷³
San Diego, California	2	NA	NA	DM (2), corticosteroid use (2)	Rhino-orbital-cerebral (2)	2/2	Dallalzadeh et al. ⁶⁹
Dover, Delaware	1	41	M	DM	Rhino-cerebral	no	Alekseyev et al. ³⁶
Lewes, Delaware	1	56	M	ESRD, corticosteroid use	Lung	Yes	Kanwar et al. ⁶⁸
Yuma, Arizona	1	49	M	Corticosteroid use	Lung	Yes	Placik et al. ²⁵
European Union	9					6 (67%)	
Multisite, the Netherlands	4	50–70	M (4)	DM (2), corticosteroid use (1), obesity (1)	Lung (3), orbital (1)	3/4	Buil et al. ¹¹
Barcelona, Spain	2	62, 48	M (2)	Kidney transplant (2), DM (1), corticosteroid use (2)	Rhinosinusal (1), Musculoskeletal (1)	0/2	Arana et al. ³¹
Besançon, France	1	55	M	Lymphoma	Lung	Yes	Bellanger et al. ⁷²
Sassari, Italy	1	66	M	Hypertension	Lung	Yes	Pasero et al. ²⁷
Graz, Austria	1	53	M	Acute myeloid leukemia	Lung	Yes	Zurl et al. ³³
Egypt	7					3 (42.8%)	
Cairo	7	41–67	M (4) F (3)	DM (6)	Rhino-orbital-cerebral (7)	3/7	Ashour et al. ²⁹
Middle East	29					15 (52%)	
Tehran, Iran	1	61	M	Corticosteroid use	Rhino-orbito-cerebral	no	Karimi-Galougahi et al. ¹⁵
Tehran, Iran	2	40, 54	M (1) F (1)	Corticosteroid use (2)	Rhino-orbital (1), rhino-orbital-cerebral (1)	1/2	Veisi et al. ³²
Tehran, Iran	15	14–71	M (9) F (6)	DM (13), corticosteroid use (7)	Rhino-orbital (15)	7/15	Pakdel et al. ¹²
Kayseri, Turkey	11	61–88	M (9) F (2)	DM (8), corticosteroid use (11)	Sino-orbital (11)	7/11	Bayram et al. ³⁰
India	3129					412/3106 (13%)	
Chandigarh	1	55	M	DM, ESRD, corticosteroid use	Lung	no	Garg et al. ⁴⁰
Mangalore, Karnataka	1	32	F	DM	Rhino-orbital-cerebral	no	Saldanha et al. ⁴⁵
Mangalore, Karnataka	1	NA	F	DM	Rhino-orbital-cerebral	no	Revannavar et al. ⁴³

(continued on next page)

Table 1 (continued)

Geographic areas	Case no.	Age (yr)	Gender	Underlying condition	Lesion	Mortality	Author
Mysuru, Karnataka	2	34, 50	M (2)	Nil	Rhino-orbital (2)	0/2	Sai Krishna et al. ⁴⁴
Bangalore, Karnataka	1	66	M	DM, corticosteroid use	Rhino-orbital	no	Rao et al. ⁴²
Bangalore, Karnataka	17	35–73	M (14) F (3)	DM (16), corticosteroid use (16)	Rhino-orbito-cerebral (17)	6/17	Moorthy et al. ⁴¹
Puducherry	10	23–67	M (8) F (2)	DM (5), corticosteroid use (10)	Orbital (10)	4/10	Sarkar et al. ⁴⁶
Ahmedabad, Gujarat	1	42	M	DM, corticosteroid use	Rhino-orbital	no	Selarka et al. ¹⁴
Ahmedabad, Gujarat	2	25, 47	M (2)	Kidney transplant (2), DM (2)	Rhino-orbital (1), lung (1)	2/2	Meshram et al. ⁴⁷
Ahmedabad, Gujarat	19	NA	NA	DM (19), corticosteroid use (19)	Rhino-orbital (19)	3/19	Ravani et al. ⁴⁹
Bikaner, Rajasthan	5	52–70	M (1) F (4)	DM (5)	Rhino-orbital (5)	2/5	Nehara et al. ⁴⁸
Jaipur, Rajasthan	23	NA	NA	NA	Rhino-orbital-cerebral (23)	NA	Sharma et al. ⁵⁰
Hyderabad, Telangana; Mumbai, Maharashtra	6	46–74	M (6)	DM (6), corticosteroid use (5)	Rhino-orbital (6)	0/6	Sen et al. ⁵³
Mumbai, Maharashtra	1	60	M	DM	Rhino-orbital	Yes	Mehta et al. ²⁶
Mumbai, Maharashtra	1	38	M	Corticosteroid use	Rhino-orbital-cerebral	no	Maini et al. ⁵²
Mumbai, Maharashtra	25	NA	NA	DM (22), HIV (2), corticosteroid use (25)	Rhino-orbital-cerebral (25)	14/25	Joshi et al. ⁵¹
Multicenter	187	57 ^a	M (150) F (37)	DM (113), corticosteroid use (146), kidney transplant (3)	Rhino-orbital (117), rhino-orbital-cerebral (44), lung (16), kidney (1), disseminated (4), others (5)	75/170	Patel et al. ¹³
102 centers	2826	12–88	M (1993) F (833)	DM (2194), hypertension (690), renal failure (88)	Rhino-orbital-cerebral (2826)	305/2218	Sen et al. ³⁸

^a Mean \pm SD, 56.9 \pm 12.5.

Note. M: man; F: female; DM, diabetes mellitus; ESRD, end stage renal disease; HIV, human immunodeficiency virus; NA, not applicable.

patients that requires critical care.⁶⁴ The combination of steroid therapy and diabetes mellitus can augment immunosuppression and hyperglycemia, increasing the risk of mucormycosis.⁶⁴ Most cases were reported from India in the literature.⁴¹ Even though a rather high regional prevalence in India, a 2.1-fold rise in mucormycosis during the COVID-19 pandemic than previous year was noted.¹³ The median time interval between COVID-19 diagnosis and the first evidence of a mucormycosis infection was 7–15 days.^{38,63}

Cases of mucormycosis may occur in COVID-19 patients without diabetes mellitus and only with mild-to-moderate diseases outside intensive care units, as reported in the Netherlands.¹¹ Although severe or critical COVID-19 in poorly controlled diabetic patients is the most perfect storm for mucormycosis,⁶⁵ receiving corticosteroids might contribute to the emergence of mucormycosis in COVID-19 patients even without critical severity and a risk comorbidity.¹¹

High counts of *Mucorales* spores in both the indoor and outdoor environments are possible additional predisposing factors. The environmental factors might contribute to the “hot-spot” regions of CAM in the world, such as the cities of Bangalore, Ahmedabad, Jaipur, and Mumbai in India (Table 1). *Mucorales* were isolated from the soil samples of different geographical locations in India, including the most common isolate of *Rhizopus arrhizus* (24.6%), followed by *Lichtheimia* spp. (23.2%), *Cunninghamella* spp. (21.7%), *Rhizopus microsporus* (14%) and *Apophysomyces* spp. (4.5%).⁶⁶ However, there are very few data concerning correlation of the environmental levels of zygomycete sporangiospores with zygomycosis, particularly in geographical areas where zygomycosis is highly prevalent.⁶⁷

Furthermore, severe COVID-19 disease is associated with an increase in pro-inflammatory markers, such as interleukin (IL)-1, IL-6, and therapy with IL-6 receptor antagonist might be at a higher risk for fungal infections.⁶⁸ COVID-19 may affect the immune system leading to lymphopenia, dysregulation of CD4 interferon-gamma expression, and reduced numbers of T lymphocytes, CD4+T cells, and CD8+T cells, altering the innate immunity.³⁹

Clinical manifestations

Uncontrolled diabetes mellitus was the most common underlying conditions contributed to CAM.^{13,37,38} Additionally, other immunocompromised conditions, including neutropenia, end-stage kidney disease, hematologic malignancy, solid organ transplant recipients and the use of corticosteroid have been reported.^{11–13,16,31–33,40} In one large series of COVID-19 associated rhino-orbital-cerebral mucormycosis, diabetes mellitus was presented in 78% of 2826 patients, and 87% had been treated with corticosteroid.³⁸ Another study of 187 CAM cases showed the similar thing that 78.1% of patients had received corticosteroid and 60.4% of patients had diabetes mellitus.¹³ However, COVID-19 could be the only underlying disease in 32.6% of CAM patients.¹³ The most common involved site of CAM was rhino-orbital cerebral, but lung, kidney, cutaneous, stomach, mediastinal lymph node, heart, pericardium, kidney, musculoskeletal and disseminated infections have been reported (Table 1).^{13,38,69,70} For patients with rhino-orbital-cerebral sinusitis, orbital/facial pain and orbital/facial

edema were the most common symptoms, followed by loss of vision, ptosis and nasal block.³⁸ Additionally, these patients could have the presentation of fever, eyelid edema, conjunctival chemosis, deteriorating visual acuity, proptosis, ophthalmoplegia, diplopia, periorbital pain, orbital/facial discoloration, cranial nerve palsy, headache, nasal blockage, ear pain, black nasal crusts, nasal discharge, periocular hypoesthesia, palatal ulcer/eschar, toothache, loose teeth, epistaxis, and facial deviation/palsy.^{12,29,38,42} CT or MRI can show sinusitis, oroantral fistula, erosions of the nasal septum, hard palate, and sinus wall, air within bony sinus structures, focal mucosal nonenhancement, panophthalmitis, orbital infiltration involving the optic nerve, skull base involvement, cerebral sinus thrombosis with secondary vasculitis, watershed acute cerebral infarctions and meningeal enhancement.^{29,51} For patient with pulmonary involvement, fever, cough, dyspnea, and hypoxia could be the presenting signs and symptoms, and the radiographic manifestations included consolidations, cavitary lung lesions and bronchopleural fistula formations with empyema.^{13,25,40,66} Although the diagnosis of CAM based on the identification of organisms in tissue by histopathology with culture confirmation, it should also require clinicians' high index of suspicion, recognition of host factors, prompt assessment of clinical manifestations and further image investigations using CT or MRI.

Microbiologic distribution

Previously, the most common reported saprophytic environmental fungi causing mucormycosis was *Rhizopus* species and other pathogens including *Mucor*, *Cunninghamella*, *Aposphysomyces*, *Lichtheimia* (formerly *Absidia*) *Saksenaea*, *Syncephalastrum*, *Bertholletia*, and *Rhizomucor* species have been reported.⁷¹ During COVID-19 pandemic, several fungi including *R. oryzae*, *R. microsporus*, *Rhizopus azygosporus*, *Lichtheimia mucor*, and *Lichtheimia ramosa* have been identified as causative pathogens.^{11,16,31,33,39,40,52,68} Rarely, CAM can have concomitant infections with *Aspergillus* species.^{41,72,73}

Treatment

First-line treatment with high-dose liposomal amphotericin B but not slow escalation is strongly recommended. Liposomal amphotericin B (5 mg/kg/day), dilute in 200 cc 5% dextrose over 2–3 h infusion, is the preferred regimen; and higher dose of 10 mg/kg/day may be given in orbital-cerebral involvement. Amphotericin B deoxycholate (1 mg/kg/day) as substantial toxicity is used only if cost and availability of liposomal amphotericin B is an issue. Patients who are intolerant to amphotericin B, alternative agents are posaconazole or isavuconazole. Both triazoles are also strongly recommended salvage treatments.^{74,75} Posaconazole or isavuconazole is often combined with liposomal amphotericin B with refractory mycosis.^{53,76} Anti-fungal therapy may be initiated with liposomal amphotericin B and posaconazole, followed by isavuconazole as salvage therapy.⁷⁷ Several case reports have shown isavuconazole to be effective as the salvage therapy for mucormycosis.^{78–80} A total of 72 clinical isolates of *Mucorales* were evaluated,

more isolates were found to be potentially susceptible to isavuconazole when compared to posaconazole.⁸¹ Successful treatment of fungal meningitis with isavuconazole in limited case reports supports brain penetration in humans.⁸² In addition to appropriate antifungal agents, the management of mucormycosis is multimodal, including reversal of underlying risk factors, such as glycemic control, and extensive or repeated surgical debridement.⁷² Surgery according to the extent of CAM involvement is important in rhino-orbitocerebral infection and in soft tissue infection and surgery intervention should be very aggressive.⁸³

Outcomes

The morbidity and mortality of CAM remain high.²³ Buil et al. reported that three of 4 CAM cases developed in the ICU and three deaths occurred in the Netherlands.¹¹ In a series of 187 CAM cases in India, the reported overall mortality was 37.4% (70/187) and 44.1% (75/170) within 6 and 12 weeks respectively.¹³ The mortality rates were substantially higher in non-prevalent regions (>50%–100% in United States and the European countries) than prevalent regions (about 40%–50% in the middle East and Egypt) and lowest (13%) in India (Table 1). However, the prognosis of mucormycosis could vary according to the site of involvement.¹³ The largest study of 2826 patients with COVID-19 associated rhino-orbital-cerebral mucormycosis in India reported the all-cause mortality was 14% ($n = 305$) of 2128 patients with available outcome data.³⁸ Although the patients with disease stage >3b (defining stage 3c: central retinal or ophthalmic artery occlusion or superior ophthalmic vein thrombosis; involvement of superior orbital fissure, inferior orbital fissure, orbital apex, loss of vision; stage 3d: bilateral orbital involvement; and stage 4) had poorer prognosis in this study, paranasal sinus debridement and orbital exenteration could significantly help reduce the mortality rate in patients with stage 4 of intracranial extension (52% versus 39%, $p < 0.05$).³⁸

Conclusion

During COVID-19 pandemic, the emergence of CAM has become a serious concern, particularly in India. Uncontrolled diabetes mellitus with DKA and the use of corticosteroid are the most common conditions among patients with CAMs. Rhino-orbital-cerebral is the most common site of involvement, but CAM can also involve pulmonary, skin and stomach. Highly suspicion and early diagnosis are the key of successful management of patients with CAM. Although the prognosis of CAM is poor, first-line high-dose liposomal amphotericin B and appropriate surgical intervention can help improve the outcome.

Ethical

Not relevant. We declare that reporting of the study was in line with the Declaration of Helsinki, as revised in 2013.

Funding

None declare.

Author contributions

Concept and design: C.-M.C., C.-C.L. and W.-L.Y. Drafting of the manuscript: C.-M.C. and C.-C.L. Critical revision of the manuscript: C.-C.L. and W.-L.Y.

Acknowledgments

None declare.

References

1. World health organization. <https://covid19.who.int/>. [Accessed 27 July 2021].
2. Lai CC, Shih TP, Ko WC, Tang HJ, Hsueh PR. Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) and coronavirus disease-2019 (COVID-19): the epidemic and the challenges. *Int J Antimicrob Agents* 2020;55:105924.
3. Lai CC, Liu YH, Wang CY, Wang YH, Hsueh SC, Yen MY, et al. Asymptomatic carrier state, acute respiratory disease, and pneumonia due to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2): facts and myths. *J Microbiol Immunol Infect* 2020;53:404–12.
4. Lai CC, Ko WC, Lee PI, Jean SS, Hsueh PR. Extra-respiratory manifestations of COVID-19. *Int J Antimicrob Agents* 2020;56:106024.
5. Lai CC, Wang CY, Hsueh PR. Co-infections among patients with COVID-19: the need for combination therapy with non-anti-SARS-CoV-2 agents? *J Microbiol Immunol Infect* 2020;53:505–12.
6. Chen WC, Lai YC, Lin CH, Zheng JF, Hung WC, Wang YJ, et al. First COVID-19 mortality case in Taiwan with bacterial coinfection by national surveillance of critically ill patients with influenza-negative pneumonia. *J Microbiol Immunol Infect* 2020;53:652–6.
7. Musuza JS, Watson L, Parmasad V, Putman-Buehler N, Christensen L, Safdar N. Prevalence and outcomes of coinfection and superinfection with SARS-CoV-2 and other pathogens: a systematic review and meta-analysis. *PLoS One* 2021;16:e0251170.
8. Alhumaid S, Al Mutair A, Al Alawi Z, Alshawi AM, Alomran SA, Almuhanna MS, et al. Coinfections with bacteria, fungi, and respiratory viruses in patients with SARS-CoV-2: a systematic review and meta-analysis. *Pathogens* 2021;10:809.
9. Langford BJ, So M, Raybardhan S, Leung V, Westwood D, MacFadden DR, et al. Bacterial co-infection and secondary infection in patients with COVID-19: a living rapid review and meta-analysis. *Clin Microbiol Infect* 2020;26:1622–9.
10. Lai CC, Yu WL. COVID-19 associated with pulmonary aspergillosis: a literature review. *J Microbiol Immunol Infect* 2021;54:46–53.
11. Buil JB, van Zanten ARH, Bentvelsen RG, Rijpstra TA, Goorhuis B, van der Voort SR, et al. Case series of four secondary mucormycosis infections in COVID-19 patients, The Netherlands, December 2020 to May 2021. *Euro Surveill* 2021;26:2100510.

12. Pakdel F, Ahmadikia K, Salehi M, Tabari A, Jafari R, Mehrparvar G, et al. Mucormycosis in patients with COVID-19: a cross-sectional descriptive multicenter study from Iran. *Mycoses* 2021;64:1238–52.
13. Patel A, Agarwal R, Rudramurthy SM, Shevkani M, Xess I, Sharma R, et al. Multicenter epidemiologic study of coronavirus disease-associated mucormycosis, India. *Emerg Infect Dis* 2021;27:2349–59.
14. Selarka L, Sharma AK, Rathod G, Saini D, Patel S, Sharma VK. Mucormycosis- A dreaded complication of Covid-19. *QJM* 2021; 114:670–1.
15. Karimi-Galougahi M, Arastou S, Haseli S. Fulminant mucormycosis complicating coronavirus disease 2019 (COVID-19). *Int Forum Allergy Rhinol* 2021;11:1029–30.
16. Khatri A, Chang KM, Berlinrut I, Wallach F. Mucormycosis after Coronavirus disease 2019 infection in a heart transplant recipient - case report and review of literature. *J Mycol Med* 2021;31:101125.
17. Mekonnen ZK, Ashraf DC, Jankowski T, Grob SR, Vagefi MR, Kersten RC, et al. Acute invasive rhino-orbital mucormycosis in a patient with COVID-19-associated acute respiratory distress syndrome. *Ophthalmic Plast Reconstr Surg* 2021;37:e40–80.
18. Pan J, Tsui C, Li M, Xiao K, de Hoog GS, Verweij PE, et al. First case of rhinocerebral mucormycosis caused by *Lichtheimia ornata*, with a review of *Lichtheimia* Infections. *Mycopathologia* 2020;185:555–67.
19. Steinbrink JM, Miceli MH. Mucormycosis. *Infect Dis Clin* 2021; 35:435–52.
20. Ajmal S, Mahmood M, Abu Saleh O, Larson J, Sohail MR. Invasive fungal infections associated with prior respiratory viral infections in immunocompromised hosts. *Infection* 2018;46:555–8.
21. Peng H, Xiao J, Wan H, Shi J, Li J. Severe gastric mycormycosis infection followed by cytomegalovirus pneumonia in a renal transplant recipient: a case report and concise review of the literature. *Transplant Proc* 2019;51:556–60.
22. Seo YM, Hwang-Bo S, Kim SK, Han SB, Chung NG, Kang JH. Fatal systemic adenoviral infection superimposed on pulmonary mucormycosis in a child with acute leukemia: a case report. *Medicine (Baltim)* 2016;95:e5054.
23. Hanley B, Naresh KN, Roufousse C, Nicholson AG, Weir J, Cooke GS, et al. Histopathological findings and viral tropism in UK patients with severe fatal COVID-19: a post-mortem study. *Lancet Microbe* 2020;1:e245–53.
24. Monte Junior ESD, Santos M, Ribeiro IB, Luz GO, Baba ER, Hirsch BS, et al. Rare and fatal gastrointestinal mucormycosis (Zygomycosis) in a COVID-19 patient: a case report. *Clin Endosc* 2020;53:746–9.
25. Placik DA, Taylor WL, Wnuk NM. Bronchopleural fistula development in the setting of novel therapies for acute respiratory distress syndrome in SARS-CoV-2 pneumonia. *Radiol Case Rep* 2020;15:2378–81.
26. Mehta S, Pandey A. Rhino-orbital mucormycosis associated with COVID-19. *Cureus* 2020;12:e10726.
27. Pasero D, Sanna S, Liperi C, Piredda D, Branca GP, Casadio L, et al. A challenging complication following SARS-CoV-2 infection: a case of pulmonary mucormycosis. *Infection* 2020;49: 1055–60.
28. Fouad YA, Abdelaziz TT, Askoura A, Saleh MI, Mahmoud MS, Ashour DM, et al. Spike in rhino-orbital-cerebral mucormycosis cases presenting to a tertiary care center during the COVID-19 pandemic. *Front Med* 2021;8:645270.
29. Ashour MM, Abdelaziz TT, Ashour DM, Askoura A, Saleh MI, Mahmoud MS. Imaging spectrum of acute invasive fungal rhino-orbital-cerebral sinusitis in COVID-19 patients: a case series and a review of literature. *J Neuroradiol* 2021;48:319–24.
30. Bayram N, Ozsaygılı C, Sav H, Tekin Y, Gundogan M, Pangal E, et al. Susceptibility of severe COVID-19 patients to rhino-orbital mucormycosis fungal infection in different clinical manifestations. *Jpn J Ophthalmol* 2021;65:515–25.
31. Arana C, Cuevas Ramírez RE, Xipell M, Casals J, Moreno A, Herrera S, et al. Mucormycosis associated with COVID-19 in two kidney transplant patients. *Transpl Infect Dis* 2021;23:e13652.
32. Veisi A, Bagheri A, Eshaghi M, Rikhtehgar MH, Rezaei Kanavi M, Farjad R. Rhino-orbital mucormycosis during steroid therapy in COVID-19 patients: a case report. *Eur J Ophthalmol* 2021. 11206721211009450.
33. Zurl C, Hoenigl M, Schulz E, Hatzl S, Gorkiewicz G, Krause R, et al. Autopsy proven pulmonary mucormycosis due to *Rhizopus microsporus* in a critically ill COVID-19 patient with underlying hematological malignancy. *J Fungi (Basel)* 2021;7:88.
34. Werthman-Ehrenreich A. Mucormycosis with orbital compartment syndrome in a patient with COVID-19. *Am J Emerg Med* 2021;42:264.e265–8.
35. Waizel-Haiat S, Guerrero-Paz JA, Sanchez-Hurtado L, Calleja-Alarcon S, Romero-Gutierrez L. A case of fatal rhino-orbital mucormycosis associated with new onset diabetic ketoacidosis and COVID-19. *Cureus* 2021;13:e13163.
36. Alekseyev K, Didenko L, Chaudhry B. Rhinocerebral mucormycosis and COVID-19 pneumonia. *J Med Cases* 2021;12:85–9.
37. Raut A, Huy NT. Rising incidence of mucormycosis in patients with COVID-19: another challenge for India amidst the second wave? *Lancet Respir Med* 2021;9:e77.
38. Sen M, Honavar SG, Bansal R, Sengupta S, Rao R, Kim U, et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2,826 patients in India - collaborative OPAL-IJO Study on Mucormycosis in COVID-19 (COSMIC), Report 1. *Indian J Ophthalmol* 2021;69:1670–92.
39. Ismaiel WF, Abdelazim MH, Eldsoky I, Ibrahim AA, Alsobky ME, Zafan E, et al. The impact of COVID-19 outbreak on the incidence of acute invasive fungal rhinosinusitis. *Am J Otolaryngol* 2021;42:103080.
40. Garg D, Muthu V, Sehgal IS, Ramachandran R, Kaur H, Bhalla A, et al. Coronavirus disease (Covid-19) associated mucormycosis (CAM): case report and systematic review of literature. *Mycopathologia* 2021;186:289–98.
41. Moorthy A, Gaikwad R, Krishna S, Hegde R, Tripathi KK, Kale PG, et al. SARS-CoV-2, Uncontrolled diabetes and corticosteroids-An unholy trinity in invasive fungal infections of the maxillofacial region? A retrospective, multi-centric analysis. *J Maxillofac Oral Surg* 2021;20:1–8.
42. Rao R, Shetty AP, Nagesh CP. Orbital infarction syndrome secondary to rhino-orbital mucormycosis in a case of COVID-19: clinico-radiological features. *Indian J Ophthalmol* 2021;69: 1627–30.
43. Revannavar SM, PS S, Samaga L, VK V. COVID-19 triggering mucormycosis in a susceptible patient: a new phenomenon in the developing world? *BMJ Case Rep* 2021;14:e241663.
44. Sai Krishna D, Raj H, Kurup P, Juneja M. Maxillofacial infections in Covid-19 era-actuality or the unforeseen: 2 Case reports. *Indian J Otolaryngol Head Neck Surg* 2021:1–4. <https://doi.org/10.1007/s12070-021-02618-5>.
45. Saldanha M, Reddy R, Vincent MJ. Paranasal mucormycosis in COVID-19 patient. *Indian J Otolaryngol Head Neck Surg* 2021: 1–4. <https://doi.org/10.1007/s12070-021-02574-0>.
46. Sarkar S, Gokhale T, Choudhury SS, Deb AK. COVID-19 and orbital mucormycosis. *Indian J Ophthalmol* 2021;69:1002–4.
47. Meshram HS, Kute VB, Chauhan S, Desai S. Mucormycosis in post-COVID-19 renal transplant patients: a lethal complication in follow-up. *Transpl Infect Dis* 2021;23:e13663.
48. Nehara HR, Puri I, Singhal V, Ih S, Bishnoi BR, Sirohi P. Rhinocerebral mucormycosis in COVID-19 patient with diabetes a deadly trio: case series from the north-western part of India. *Indian J Med Microbiol* 2021;39:380–3.

49. Ravani SA, Agrawal GA, Leuva PA, Modi PH, Amin KD. Rise of the phoenix: mucormycosis in COVID-19 times. *Indian J Ophthalmol* 2021;**69**:1563–8.
50. Sharma S, Grover M, Bhargava S, Samdani S, Kataria T. Post coronavirus disease mucormycosis: a deadly addition to the pandemic spectrum. *J Laryngol Otol* 2021;**135**:442–7.
51. Joshi AR, Muthe MM, Patankar SH, Athawale A, Achhapalia Y. CT and MRI findings of invasive mucormycosis in the setting of COVID-19: experience from a single center in India. *AJR Am J Roentgenol* 2021;**217**:1431–2.
52. Maini A, Tomar G, Khanna D, Kini Y, Mehta H, Bhagyasree V. Sino-orbital mucormycosis in a COVID-19 patient: a case report. *Int J Surg Case Rep* 2021;**82**:105957.
53. Sen M, Lahane S, Lahane TP, Parekh R, Honavar SG. Mucor in a viral land: a tale of two pathogens. *Indian J Ophthalmol* 2021;**69**:244–52.
54. Chakrabarti A, Singh R. Mucormycosis in India: unique features. *Mycoses* 2014;**57**(Suppl 3):85–90.
55. Artis WM, Fountain JA, Delcher HK, Jones HE. A mechanism of susceptibility to mucormycosis in diabetic ketoacidosis: transferrin and iron availability. *Diabetes* 1982;**31**:1109–14.
56. Ibrahim AS, Gebremariam T, Lin L, Luo G, Husseiny MI, Skory CD, et al. The high affinity iron permease is a key virulence factor required for *Rhizopus oryzae* pathogenesis. *Mol Microbiol* 2010;**77**:587–604.
57. Ibrahim AS. Host-iron assimilation: pathogenesis and novel therapies of mucormycosis. *Mycoses* 2014;**57**(Suppl 3):13–7.
58. Gebremariam T, Liu M, Luo G, Bruno V, Phan QT, Waring AJ, et al. CotH3 mediates fungal invasion of host cells during mucormycosis. *J Clin Invest* 2014;**124**:237–50.
59. Alqarihi A, Gebremariam T, Gu Y, Swidergall M, Alkhazraji S, Soliman SSM, et al. GRP78 and integrins play different roles in host cell invasion during mucormycosis. *mBio* 2020;**11**. e01087-20.
60. Gumashta J, Gumashta R. COVID19 associated mucormycosis: is GRP78 a possible link? *J Infect Public Health* 2021;**14**:1351–7.
61. Gebremariam T, Lin L, Liu M, Kontoyiannis DP, French S, Edwards JE Jr, et al. Bicarbonate correction of ketoacidosis alters host-pathogen interactions and alleviates mucormycosis. *J Clin Invest* 2016;**126**:2280–94.
62. Singh AK, Singh R, Joshi SR, Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. *Diabetes Metab Syndr* 2021;**15**:102146.
63. Pal R, Singh B, Bhadada SK, Banerjee M, Bhogal RS, Hage N, et al. COVID-19-associated mucormycosis: an updated systematic review of literature. *Mycoses* 2021;**64**:1452–9.
64. Ahmadikia K, Hashemi SJ, Khodavaisy S, Getso MI, Alijani N, Badali H, et al. The double-edged sword of systemic corticosteroid therapy in viral pneumonia: a case report and comparative review of influenza-associated mucormycosis versus COVID-19 associated mucormycosis. *Mycoses* 2021;**64**:798–808.
65. John TM, Jacob CN, Kontoyiannis DP. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. *J Fungi (Basel)* 2021;**7**:298.
66. Prakash H, Ghosh AK, Rudramurthy SM, Paul RA, Gupta S, Negi V, et al. The environmental source of emerging *Apophysomyces variabilis* infection in India. *Med Mycol* 2016;**54**:567–75.
67. Richardson M. The ecology of the Zygomycetes and its impact on environmental exposure. *Clin Microbiol Infect* 2009;**15**(Suppl 5):2–9.
68. Kanwar A, Jordan A, Olewiler S, Wehberg K, Cortes M, Jackson BR. A fatal case of *Rhizopus azygosporus* pneumonia following COVID-19. *J Fungi (Basel)* 2021;**7**:174.
69. Dallalzadeh LO, Ozzello DJ, Liu CY, Kikkawa DO, Korn BS. Secondary infection with rhino-orbital cerebral mucormycosis associated with COVID-19. *Orbit* 2021;**1**–4. <https://doi.org/10.1080/01676830.2021>.
70. Krishna V, Morjaria J, Jalandari R, Omar F, Kaul S. Autoptic identification of disseminated mucormycosis in a young male presenting with cerebrovascular event, multi-organ dysfunction and COVID-19 infection. *IDCases* 2021;**25**:e01172.
71. Roden MM, Zaoutis TE, Buchanan WL, Knudsen TA, Sarkisova TA, Schaefele RL, et al. Epidemiology and outcome of zygomycosis: a review of 929 reported cases. *Clin Infect Dis* 2005;**41**:634–53.
72. Bellanger AP, Navellou JC, Lepiller Q, Brion A, Brunel AS, Millon L, et al. Mixed mold infection with *Aspergillus fumigatus* and *Rhizopus microsporus* in a severe acute respiratory syndrome Coronavirus 2 (SARS-CoV-2) patient. *Infect Dis News* 2021;**51**:633–5.
73. Johnson AK, Ghazarian Z, Cendrowski KD, Persichino JG. Pulmonary aspergillosis and mucormycosis in a patient with COVID-19. *Med Mycol Case Rep* 2021;**32**:64–7.
74. Rudramurthy SM, Hoenigl M, Meis JF, Cornely OA, Muthu V, Gangneux JP, et al. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low- and middle-income countries. *Mycoses* 2021;**64**:1028–37.
75. Cornely OA, Alastruey-Izquierdo A, Arenz D, Chen SCA, Dannaoui E, Hochhegger B, et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European confederation of medical mycology in cooperation with the mycoses study group education and research consortium. *Lancet Infect Dis* 2019;**19**:e405–21.
76. Imran M, Alshrari SA, Tauseef M, Khan SA, Hudu SA, Abida. Mucormycosis medications: a patent review. *Expert Opin Ther Pat* 2021;**31**:1059–74.
77. Miller RP, Farrugia L, Leask J, Khalsa K, Khanna N, Melia L. Successful treatment of *Rhizopus arrhizus* rhino-orbital-cerebral mucormycosis with isavuconazole salvage therapy following extensive debridement. *Med Mycol Case Rep* 2021;**32**:39–42.
78. Shafiq M, Ali Z, Ukani R, Brewer J. Isavuconazole: a promising salvage therapy for invasive mucormycosis. *Cureus* 2018;**10**:e2547.
79. Ilharco M, Pereira CM, Moreira L, Proença AL, do Carmo Fevereiro M, Lampreia F, et al. Rhinoorbital mucormycosis in the immunocompetent: experience with isavuconazole. *IDCases* 2019;**18**:e00591.
80. Ashkenazi-Hoffnung L, Bilavsky E, Levy I, Grisaru G, Sadot E, Ben-Ami R, et al. Isavuconazole as successful salvage therapy for mucormycosis in pediatric patients. *Pediatr Infect Dis J* 2020;**39**:718–24.
81. Arendrup MC, Jensen RH, Meletiadis J. In vitro activity of isavuconazole and comparators against clinical isolates of the Mucorales order. *Antimicrob Agents Chemother* 2015;**59**:7735–42.
82. Ellsworth M, Ostrosky-Zeichner L. Isavuconazole: mechanism of action, clinical efficacy, and resistance. *J Fungi (Basel)* 2020;**6**:324.
83. Honavar SG. Code Mucor: guidelines for the diagnosis, staging and management of rhino-orbital-cerebral mucormycosis in the setting of COVID-19. *Indian J Ophthalmol* 2021;**69**:1361–5.